Background Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the
inflammatory response and control the symptoms of severe coronavirus disease 2019 …

The efficacy of tocilizumab (TOC), monoclonal antibody against interleukin‐6 (IL‐6) receptor,
in patients with coronavirus disease‐2019 (COVID‐19) patients has led to conflicting results …

Abstract Coronavirus disease 2019 (COVID‐19) can lead to a massive cytokine release. The
use of the anti‐interleukin‐6 receptor monoclonal antibody tocilizumab (TCZ) has been …

Background We sought to evaluate the effect of tocilizumab (TCB), a recombinant
humanized monoclonal antibody against soluble interleukin‐6 receptors, in patients …

Fowler et al. 1 proposed RNA RT-LAMP as a rapid and accurate tool to promptly identify
highly contagious individuals during the pandemic era. In the current vaccination era, it …

Background Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking
downstream pro-inflammatory effects of IL-6. In preliminary reports it was suggested to be …

Objectives To describe the clinical characteristics and predictors of major outcomes in
patients treated with tocilizumab (TCZ) for severe COVID-19 pneumonia. Patients and …

Background Severe coronavirus disease 2019 (COVID-19) can manifest in rapid
decompensation and respiratory failure with elevated inflammatory markers, consistent with …

The severe acute respiratory syndrome coronavirus‑2 (SARS‑CoV‑2) pandemic is a
significant global issue that has major implications for the healthcare system. The mortality …

Tocilizumab decreases inflammatory response in the cytokine storm which is one of the
mechanisms behind the development of ARDS in COVID-19 patients. The objective of our …